Related Experiment Video
Updated: Jul 9, 2026

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
Published on: April 25, 2022
[Genotype analysis of CYP1A2 IVS4 + 43A/G in patients with prostate cancer]
Jing-ping Ge1, Wu Wei, Xue-jun Shang
1Department of Urology, Nanjing General Hospital of Nanjing Command, PLA, Nanjing, Jiangsu 210002, China.
Objective:
To investigate the genotype of the single nucleotide polymorphisms(SNP) of CYP1A2 IVS4 + 43A/G in patients with prostate cancer by TaqMan allelic discrimination.
Methods:
TaqMan SNP allelic discrimination was performed with the ABI 7300 system to detect the genotype of CYP1A2 IVS4 + 43A/G in 85 patients with prostate cancer.
Results:
The genotypes of CYP1A2 IVS4 + 43A/G in the patients were as follows: AA subtype in 5 cases (5.9%), AG in 33 (38.8%), and GG in 47 (55.3%). Each subtype of CYP1A2 IVS4 + 43A/G was not correlated with the Gleason score of prostate cancer.
Conclusion:
There was no significant correlation between SNP of CYP1A2 and the differentiation of prostate cancer.
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Single Nucleotide Polymorphisms-SNPs
